HIV therapy
- Antiretroviral naïve and switch studies (commercial and academic)
- Primary HIV infection
- Antiretroviral pharmacology and pharmacokinetic studies
- New strategies eg dual therapy & test and treat
Comorbidities and HIV
- Effects of ageing on HIV disease
- Cognitive Impairment
- HIV and other conditions eg Diabetes, renal disease, liver disease, bone disease
- Complications of antiretroviral therapy
- Frailty in HIV
- Hepatitis B & C
HIV prevention and eradication
- HIV Pre exposure prophylaxis and post exposure prophylaxis
- HIV Eradication / Cure strategies and studies
Sexual Health Research
- New treatments for sexually transmitted infections (STI)
- Vaccinations as STI prevention
Innovation & technology
- Use of M-health platforms in HIV & Sexual Health eg Apps
- Advances in diagnostics
Examples of some of the previous research studies carried out with our team:
0111 – Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
0112 – Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
0109 – Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
1089 – Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
1844 (Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF )
1489 (Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine )
1878 (Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide )
0109 (Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination)
0122 (Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection)
2055 (DISCOVER PrEP study)
DRIVE SHIFT
DRIVE FORWARD
DRIVE AHEAD
EMERALD
RIVER
START – Strategic Timing of AntiRetroviral Treatment
047 – A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine
056 – Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity
058 – Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
060 (NEAT) – Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG).
Also see article printed in NAM
064 – Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over
058
064
056
ONCE
IMPACT – NHS England PrEP study
PRIME
POSITIVE VOICES
POPPY
POPPY SLEEP (Sub study of POPPY)
